Profiles

1.	Edwards MS, Nicholson-Weller A, Baker CJ, Kasper DL. The role of specific antibody in alternative complement pathway-mediated opsonophagocytosis of type III, group B Streptococcus. J Exp Med. 1980 May 1; 151(5):1275-87.
2.	Burge J, Nicholson-Weller A, Austen KF. Isolation of C4-binding protein from guinea pig plasma and demonstration of its function as a control protein of the classical complement pathway C3 convertase. J Immunol. 1981 Jan; 126(1):232-5.
3.	Burge J, Nicholson-Weller A, Austen KF. Isolation of the fourth component of guinea pig complement and its single polypeptide chain precursor from plasma. Mol Immunol. 1981 Jan; 18(1):47-54.
4.	Nicholson-Weller A, Daha MR, Austen KF. Different functions for specific guinea pig IgG1 and IgG2 in the lysis of sheep erythrocytes by C4-deficient guinea pig serum. J Immunol. 1981 May; 126(5):1800-4.
5.	Nicholson-Weller A, Burge J, Austen KF. Purification from guinea pig erythrocyte stroma of a decay-accelerating factor for the classical c3 convertase, C4b,2a. J Immunol. 1981 Nov; 127(5):2035-9.
6.	Edwards MS, Kasper DL, Jennings HJ, Baker CJ, Nicholson-Weller A, et al. Capsular sialic acid prevents activation of the alternative complement pathway by type III, group B streptococci. J Immunol. 1982 Mar; 128(3):1278-83.
7.	Daha MR, Bertina RM, Thompson J, Kauffmann RH, Nicholson-Weller A, Veltkamp JJ, Briët E. Combined hereditary deficiency of the sixth component of complement and factor VIII coagulant activity in a Dutch family. Clin Exp Immunol. 1982 Jun; 48(3):733-8.
8.	Markham RB, Nicholson-Weller A, Schiffman G, Kasper DL. The presence of sialic acid on two related bacterial polysaccharides determines the site of the primary immune response and the effect of complement depletion on the response in mice. J Immunol. 1982 Jun; 128(6):2731-3.
9.	Nicholson-Weller A, Burge J, Fearon DT, Weller PF, Austen KF, et al. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J Immunol. 1982 Jul; 129(1):184-9.
10.	Eads ME, Levy NJ, Kasper DL, Baker CJ, Nicholson-Weller A. Antibody-independent activation of C1 by type Ia group B streptococci. J Infect Dis. 1982 Nov; 146(5):665-72.
11.	Nicholson-Weller A, March JP, Rosenfeld SI, Austen KF, et al. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc Natl Acad Sci U S A. 1983 Aug; 80(16):5066-70.
12.	Levy NJ, Nicholson-Weller A, Baker CJ, Kasper DL. Potentiation of virulence by group B streptococcal polysaccharides. J Infect Dis. 1984 Jun; 149(6):851-60.
13.	Edwards MS, Kasper DL, Nicholson-Weller A, Baker CJ. The role of complement in opsonization of GBS. Antibiot Chemother. 1985; 35:170-89.
14.	Roberts WN, Wilson JG, Wong W, Jenkins DE, Fearon DT, Austen KF, Nicholson-Weller A, et al. Normal function of CR1 on affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria. J Immunol. 1985 Jan; 134(1):512-7.
15.	Nicholson-Weller A, Spicer DB, Austen KF, et al. Deficiency of the complement regulatory protein, "decay-accelerating factor," on membranes of granulocytes, monocytes, and platelets in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1985 Apr 25; 312(17):1091-7.
16.	Nicholson-Weller A, March JP, Rosen CE, Spicer DB, Austen KF, et al. Surface membrane expression by human blood leukocytes and platelets of decay-accelerating factor, a regulatory protein of the complement system. Blood. 1985 May; 65(5):1237-44.
17.	Hu VW, Nicholson-Weller A. Enhanced complement-mediated lysis of type III paroxysmal nocturnal hemoglobinuria erythrocytes involves increased C9 binding and polymerization. Proc Natl Acad Sci U S A. 1985 Aug; 82(16):5520-4.
18.	Shin ML, Hänsch G, Hu VW, Nicholson-Weller A, et al. Membrane factors responsible for homologous species restriction of complement-mediated lysis: evidence for a factor other than DAF operating at the stage of C8 and C9. J Immunol. 1986 Mar 1; 136(5):1777-82.
19.	Nicholson-Weller A, Russian DA, Austen KF, et al. Natural killer cells are deficient in the surface expression of the complement regulatory protein, decay accelerating factor (DAF). J Immunol. 1986 Aug 15; 137(4):1275-9.
20.	Nicholson-Weller A, Zaia J, Raum MG, Coligan JE. Decay accelerating factor (DAF) peptide sequences share homology with a consensus sequence found in the superfamily of structurally related complement proteins and other proteins including haptoglobin, factor XIII, beta 2-glycoprotein I, and the IL-2 receptor. Immunol Lett. 1987 Apr; 14(4):307-11.
21.	Hu VW, Mazorow DL, Nicholson-Weller A, Shin ML. Enhancement of complement-mediated lysis of dithiothreitol-treated erythrocytes involves increased C9 insertion and polymerization. Mol Immunol. 1987 Aug; 24(8):887-96.
22.	Halperin JA, Nicholson-Weller A, Brugnara C, Tosteson DC. Complement induces a transient increase in membrane permeability in unlysed erythrocytes. J Clin Invest. 1988 Aug; 82(2):594-600.
23.	Hänsch GM, Weller PF, Nicholson-Weller A. Release of C8 binding protein (C8bp) from the cell membrane by phosphatidylinositol-specific phospholipase C. Blood. 1988 Sep; 72(3):1089-92.
24.	Halperin JA, Nicholson-Weller A. Paroxysmal nocturnal hemoglobinuria. A complement-mediated disease. Complement Inflamm. 1989; 6(1):65-72.
25.	Lucey DR, Dorsky DI, Nicholson-Weller A, Weller PF. Human eosinophils express CD4 protein and bind human immunodeficiency virus 1 gp120. J Exp Med. 1989 Jan 1; 169(1):327-32.
26.	Nicholson-Weller A, Halperin JA. Mechanisms by which the erythrocyte protects itself from complement damage. Prog Clin Biol Res. 1989; 297:263-70; discussion 270-1.
27.	Simmons DL, Tan S, Tenen DG, Nicholson-Weller A, Seed B, et al. Monocyte antigen CD14 is a phospholipid anchored membrane protein. Blood. 1989 Jan; 73(1):284-9.
28.	Lucey DR, Nicholson-Weller A, Weller PF. Mature human eosinophils have the capacity to express HLA-DR. Proc Natl Acad Sci U S A. 1989 Feb; 86(4):1348-51.
29.	Quigg RJ, Nicholson-Weller A, Cybulsky AV, Badalamenti J, Salant DJ, et al. Decay accelerating factor regulates complement activation on glomerular epithelial cells. J Immunol. 1989 Feb 1; 142(3):877-82.
30.	Halperin JA, Brugnara C, Nicholson-Weller A, et al. Ca2+-activated K+ efflux limits complement-mediated lysis of human erythrocytes. J Clin Invest. 1989 May; 83(5):1466-71.
31.	Lopez-Trascasa M, Bing DH, Rivard M, Nicholson-Weller A. Factor J: isolation and characterization of a new polypeptide inhibitor of complement C1. J Biol Chem. 1989 Sep 25; 264(27):16214-21.
32.	Marques MB, Weller PF, Parsonnet J, Ransil BJ, Nicholson-Weller A. Phosphatidylinositol-specific phospholipase C, a possible virulence factor of Staphylococcus aureus. J Clin Microbiol. 1989 Nov; 27(11):2451-4.
33.	Weller PF, Ackerman SJ, Nicholson-Weller A, Dvorak AM, et al. Cytoplasmic lipid bodies of human neutrophilic leukocytes. Am J Pathol. 1989 Nov; 135(5):947-59.
34.	Yamamoto H, Blaas P, Nicholson-Weller A, Hänsch GM. Homologous species restriction of the complement-mediated killing of nucleated cells. Immunology. 1990 Aug; 70(4):422-6.
35.	Laclette JP, Shoemaker CB, Richter D, Arcos L, Pante N, Cohen C, Bing D, Nicholson-Weller A. Paramyosin inhibits complement C1. J Immunol. 1992 Jan 1; 148(1):124-8.
36.	Nicholson-Weller A. Decay accelerating factor (CD55). Curr Top Microbiol Immunol. 1992; 178:7-30.
37.	Mahoney JF, Urakaze M, Hall S, DeGasperi R, Chang HM, Sugiyama E, Warren CD, Borowitz M, Nicholson-Weller A, Rosse WF, et al. Defective glycosylphosphatidylinositol anchor synthesis in paroxysmal nocturnal hemoglobinuria granulocytes. Blood. 1992 Mar 15; 79(6):1400-3.
38.	Finberg RW, White W, Nicholson-Weller A. Decay-accelerating factor expression on either effector or target cells inhibits cytotoxicity by human natural killer cells. J Immunol. 1992 Sep 15; 149(6):2055-60.
39.	Halperin JA, Taratuska A, Rynkiewicz M, Nicholson-Weller A. Transient changes in erythrocyte membrane permeability are induced by sublytic amounts of the complement membrane attack complex (C5b-9). Blood. 1993 Jan 1; 81(1):200-5.
40.	Nicholson-Weller A, Halperin JA. Membrane signaling by complement C5b-9, the membrane attack complex. Immunol Res. 1993; 12(3):244-57.
41.	Ackerman SJ, Corrette SE, Rosenberg HF, Bennett JC, Mastrianni DM, Nicholson-Weller A, Weller PF, Chin DT, Tenen DG, et al. Molecular cloning and characterization of human eosinophil Charcot-Leyden crystal protein (lysophospholipase). Similarities to IgE binding proteins and the S-type animal lectin superfamily. J Immunol. 1993 Jan 15; 150(2):456-68.
42.	Halperin JA, Taratuska A, Nicholson-Weller A. Terminal complement complex C5b-9 stimulates mitogenesis in 3T3 cells. J Clin Invest. 1993 May; 91(5):1974-8.
43.	Landa A, Laclette JP, Nicholson-Weller A, Shoemaker CB. cDNA cloning and recombinant expression of collagen-binding and complement inhibitor activity of Taenia solium paramyosin (AgB). Mol Biochem Parasitol. 1993 Aug; 60(2):343-7.
44.	Benzaquen LR, Nicholson-Weller A, Halperin JA. Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells. J Exp Med. 1994 Mar 1; 179(3):985-92.
45.	Nicholson-Weller A, Wang CE. Structure and function of decay accelerating factor CD55. J Lab Clin Med. 1994 Apr; 123(4):485-91.
46.	Jack RM, Lowenstein BA, Nicholson-Weller A. Regulation of C1q receptor expression on human polymorphonuclear leukocytes. J Immunol. 1994 Jul 1; 153(1):262-9.
47.	Wang C, Barbashov S, Jack RM, Barrett T, Weller PF, Nicholson-Weller A. Hemolytically inactive C5b67 complex: an agonist of polymorphonuclear leukocytes. Blood. 1995 May 1; 85(9):2570-8.
48.	Wang C, Gerard NP, Nicholson-Weller A, et al. Signaling by hemolytically inactive C5b67, an agonist of polymorphonuclear leukocytes. J Immunol. 1996 Jan 15; 156(2):786-92.
49.	Butko P, Nicholson-Weller A, Wessels MR. Role of complement and complement receptor C1qR in the antibody-independent killing of group B streptococcus. Adv Exp Med Biol. 1997; 418:941-3.
50.	Barbashov SF, Wang C, Nicholson-Weller A. Serum amyloid P component forms a stable complex with human C5b6. J Immunol. 1997 Apr 15; 158(8):3830-5.
51.	Fischer MB, Prodeus AP, Nicholson-Weller A, Ma M, Murrow J, Reid RR, Warren HB, Lage AL, Moore FD, Rosen FS, Carroll MC, et al. Increased susceptibility to endotoxin shock in complement C3- and C4-deficient mice is corrected by C1 inhibitor replacement. J Immunol. 1997 Jul 15; 159(2):976-82.
52.	Klickstein LB, Barbashov SF, Liu T, Jack RM, Nicholson-Weller A. Complement receptor type 1 (CR1, CD35) is a receptor for C1q. Immunity. 1997 Sep; 7(3):345-55.
53.	Nicholson-Weller A, Klickstein LB. C1q-binding proteins and C1q receptors. Curr Opin Immunol. 1999 Feb; 11(1):42-6.
54.	Mondragón-Palomino M, Piñero D, Nicholson-Weller A, Laclette JP. Phylogenetic analysis of the homologous proteins of the terminal complement complex supports the emergence of C6 and C7 followed by C8 and C9. J Mol Evol. 1999 Aug; 49(2):282-9.
55.	Wang C, Bozza PT, Barbashov SF, Sauty A, Nicholson-Weller A. In vitro and in vivo responses of murine granulocytes to human complement-derived, haemolytically inactive C5b67 (iC5b67). Clin Exp Immunol. 1999 Aug; 117(2):261-8.
56.	Butko P, Nicholson-Weller A, Wessels MR. Role of complement component C1q in the IgG-independent opsonophagocytosis of group B streptococcus. J Immunol. 1999 Sep 1; 163(5):2761-8.
57.	Tas SW, Klickstein LB, Barbashov SF, Nicholson-Weller A. C1q and C4b bind simultaneously to CR1 and additively support erythrocyte adhesion. J Immunol. 1999 Nov 1; 163(9):5056-63.
58.	Tyagi S, Nicholson-Weller A, Barbashov SF, Tas SW, Klickstein LB. Intercellular adhesion molecule 1 and beta2 integrins in C1q-stimulated superoxide production by human neutrophils: an example of a general regulatory mechanism governing acute inflammation. Arthritis Rheum. 2000 Oct; 43(10):2248-59.
59.	Tyagi S, Klickstein LB, Nicholson-Weller A, et al. C5a-stimulated human neutrophils use a subset of beta2 integrins to support the adhesion-dependent phase of superoxide production. J Leukoc Biol. 2000 Nov; 68(5):679-86.
60.	Morgan BP, Daha M, Meri S, Nicholson-Weller A. Into the third century of complement research. Immunol Today. 2000 Dec; 21(12):603-5.
61.	Ghiran I, Barbashov SF, Klickstein LB, Tas SW, Jensenius JC, Nicholson-Weller A. Complement receptor 1/CD35 is a receptor for mannan-binding lectin. J Exp Med. 2000 Dec 18; 192(12):1797-808.
62.	Ghiran I, Tyagi SR, Klickstein LB, Nicholson-Weller A. Expression and function of C1q receptors and C1q binding proteins at the cell surface. Immunobiology. 2002 Sep; 205(4-5):407-20.
63.	Ghiran I, Klickstein LB, Nicholson-Weller A. Calreticulin is at the surface of circulating neutrophils and uses CD59 as an adaptor molecule. J Biol Chem. 2003 Jun 6; 278(23):21024-31.
64.	Levy O, Jean-Jacques RM, Cywes C, Sisson RB, Zarember KA, Godowski PJ, Christianson JL, Guttormsen HK, Carroll MC, Nicholson-Weller A, Wessels MR. Critical role of the complement system in group B streptococcus-induced tumor necrosis factor alpha release. Infect Immun. 2003 Nov; 71(11):6344-53.
65.	Otabor I, Tyagi S, Beurskens FJ, Ghiran I, Schwab P, Nicholson-Weller A, Klickstein LB. A role for lipid rafts in C1q-triggered O2- generation by human neutrophils. Mol Immunol. 2004 Jun; 41(2-3):185-90.
66.	Pilsczek FH, Nicholson-Weller A, Ghiran I. Phagocytosis of Salmonella montevideo by human neutrophils: immune adherence increases phagocytosis, whereas the bacterial surface determines the route of intracellular processing. J Infect Dis. 2005 Jul 15; 192(2):200-9.
67.	Honczarenko M, Lu B, Nicholson-Weller A, Gerard NP, Silberstein LE, Gerard C. C5L2 receptor is not involved in C3a / C3a-desArg-mediated enhancement of bone marrow hematopoietic cell migration to CXCL12. Leukemia. 2005 Sep; 19(9):1682-3; author reply 1684-5.
68.	Honczarenko M, Ratajczak MZ, Nicholson-Weller A, Silberstein LE. Complement C3a enhances CXCL12 (SDF-1)-mediated chemotaxis of bone marrow hematopoietic cells independently of C3a receptor. J Immunol. 2005 Sep 15; 175(6):3698-706.
69.	Chen CH, Ghiran I, Beurskens FJ, Weaver G, Vincent JA, Nicholson-Weller A, Klickstein LB. Antibody CR1-2B11 recognizes a non-polymorphic epitope of human CR1 (CD35). Clin Exp Immunol. 2007 Jun; 148(3):546-54.
70.	Costa M, Ghiran I, Peng CK, Nicholson-Weller A, Goldberger AL. Complex dynamics of human red blood cell flickering: alterations with in vivo aging. Phys Rev E Stat Nonlin Soft Matter Phys. 2008 Aug; 78(2 Pt 1):020901.
71.	Ghiran I, Glodek AM, Weaver G, Klickstein LB, Nicholson-Weller A. Ligation of erythrocyte CR1 induces its clustering in complex with scaffolding protein FAP-1. Blood. 2008 Oct 15; 112(8):3465-73.

 

Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.

Nicholson-Weller's...